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Abstract. The Amaryllidaceae alkaloids represent a large (over 300 
alkaloids have been isolated) and still expanding group of 
biogenetically related isoquinoline alkaloids that are found 
exclusively in plants belonging to this family. In spite of their great 
variety of pharmacological and/or biological properties, only 
galanthamine is used therapeutically. First isolated from Galanthus 
species, this alkaloid is a long-acting, selective, reversible and 
competitive inhibitor of acetylcholinesterase, and is used for the 
treatment of Alzheimer’s disease. Other Amaryllidaceae alkaloids 
of pharmacological interest will also be described in this chapter.  
 
Introduction 
 
 The Amaryllidaceae are richly represented in the tropics and               
have pronounced centers of diversity in South-Africa and the Andean region. 
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Some genera are also found in the Mediterranean area and temperate regions 
of Asia. 
 A particular characteristic of Amaryllidaceae is a consistent presence of 
an exclusive group of alkaloids, which have been isolated from the plants of 
all the genera of this family. The Amaryllidaceae alkaloids represent a large 
and still expanding group of isoquinoline alkaloids, the majority of which are 
not known to occur in any other family of plants. Since the isolation of the 
first alkaloid, lycorine, from Narcissus pseudonarcissus in 1877, substantial 
progress has been made in examining the Amaryllidaceae plants, although 
they still remain a relatively untapped phytochemical source [1]. At present, 
over 300 alkaloids have been isolated from plants of this family [2] and, 
although their structures vary considerably, these alkaloids are considered to 
be biogenetically related. 
 The large number of structurally diverse Amaryllidaceae alkaloids are 
classified mainly into nine skeleton types, for which the representative 
alkaloids are: norbelladine, lycorine, homolycorine, crinine, haemanthamine, 
narciclasine, tazettine, montanine and galanthamine (Fig. 1). With the aim of 
unifying the numbering system of the different skeleton types, Ghosal’s model 
will be used in this review [3]. 
 As the alkaloids of the Amaryllidaceae family species fall mainly into one 
of these subgroups, they can serve as a classifying tool for including genera 
and species in this family. Recently, Unver and Jin have proposed subgroups 
for some skeleton types, according to the structures of new alkaloids isolated 
from Galanthus species [4,5]. Furthermore, although it is unusual to find other 
types of alkaloids in this family, if present, they are always accompanied by 
typical Amaryllidaceae alkaloids. The classical example is the reported 
presence of the mesembrane (Sceletium) alkaloids, generally found in the 
Aizoaceae family [6,7], in a few species of Amaryllidaceae such as 
Hymenocallis arenicola, Crinum oliganthum, Narcissus pallidulus and 
Narcissus triandrus [8-10]. In turn, the unexpected isolation of (−)-capnoidine 
and (+)-bulbocapnine from Galanthus nivalis subsp. cilicicus is the first report 
of the occurrence of classical isoquinoline alkaloids in a typical member of the 
Amaryllidaceae [11]. 
 Plants of the Amaryllidaceae family have been used for thousands of 
years as herbal remedies. The alkaloids from their extracts have been the 
object of active chemical investigation for nearly 200 years. Over the past 
three decades many have been isolated, screened for different biological 
activities, and synthesized by a number of research groups.  
 The structural elucidation of the Amaryllidaceae alkaloids and their 
biological profiles, as well as their synthesis, have been summarized in the last 
few years [12-14], which, together with the regular publications of the journal 
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Figure 1. Amaryllidaceae alkaloid types. 
 
Natural Products Reports [5,15-17] over the last decade, represents a valuable 
source of information.   
 The present review provides coverage of the biosynthesis, NMR 
spectroscopy and biological activity of the Amaryllidaceae alkaloids up to the 
end of 2010. 
 
1. Biosynthetic pathways 
  
 Most of the biosynthetic research done on Amaryllidaceae alkaloids was 
carried out in the sixties and early seventies. Since then, the only noteworthy 
study has been the biosynthesis of galanthamine and related alkaloids [18]. As 
in most alkaloid biosyntheses, that of the Amaryllidaceae follows a pattern 
made up of certain steps. 
 
1.1. Enzymatic preparation of the precursors 
  
 Although L-phenylalanine (L-phe) and L-tyrosine (L-tyr) are closely related 
in chemical structure, they are not interchangeable in plants. In the 
Amaryllidaceae alkaloids, L-phe serves as a primary precursor of the C6-C1 
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fragment, corresponding to ring A and the benzylic position (C-6), and L-tyr is 
the precursor of ring C, the two-carbon side chain (C-11 and C-12) and 
nitrogen, C6-C2-N. The conversion of L-phe to the C6-C1 unit requires the loss 
of two carbon atoms from the side chain as well as the introduction of at least 
two oxygenated substituents into the aromatic ring, which is performed via 
cinnamic acids. The presence of the enzyme phenylalanine ammonia lyase 
(PAL) has been demonstrated in Amaryllidaceae plants [19] and the elimination 
of ammonia mediated by this enzyme is known to occur in an antiperiplanar 
manner to give trans-cinnamic acid, with loss of the β-pro-S hydrogen [20]. 
Thus, it may be expected that L-phe would be incorporated into Amaryllidaceae 
alkaloids with retention of the β-pro-R hydrogen. However, feeding 
experiments in Narcissus ‘King Alfred’ showed that tritium originally present at 
C-β of L-phe, whatever the configuration, was lost in the formation of several 
haemanthamine and homolycorine type alkaloids, which led to the conclusion 
that fragmentation of the cinnamic acids involves oxidation of C-β to ketone or 
acid level, the final product being protocatechuic aldehyde or its derivatives 
(Fig. 2). On the other hand, L-tyr is degraded no further than tyramine before 
incorporation into the Amaryllidaceae alkaloids. 
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Figure 2. Biosynthetic pathway to norbelladine. 
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1.2. Primary cyclization mechanisms 
  
 Tyramine and protocatechuic aldehyde or its derivatives are logical 
components for the biosynthesis of the precursor norbelladine. This pivotal 
reaction represents the entry of primary metabolites into a secondary 
metabolic pathway. The junction of the amine and the aldehyde results in a 
Schiff’s base, two of which have been isolated up to now from several Crinum 
species: craugsodine [21] and isocraugsodine [22]. The existence of Schiff’s 
bases in nature as well as their easy conversion into the different ring-systems 
of the Amaryllidaceae alkaloids suggest that the initial hypothesis about this 
biosynthetic pathway was correct. 
 
1.3. Enzymatic preparation of intermediates 
  
 In 1957, Barton and Cohen [23] proposed that norbelladine or related 
compounds could undergo oxidative coupling in Amaryllidaceae plants, once 
ring A had been suitably protected by methylation, resulting in the different 
skeletons of the Amaryllidaceae alkaloids (Fig. 3).  The key intermediate in 
most of cases is O-methylnorbelladine. 
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Figure 3. Phenol oxidative coupling in Amaryllidaceae. 
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1.4. Secondary cyclization, diversification and restructuring 
  
 Secondary cyclization is produced by an oxidative coupling of                     
O-methylnorbelladine. 
 
1.4.1. Lycorine and homolycorine types 
  
 The alkaloids of this group are derivatives of the pyrrolo[de]phenan-
thridine (lycorine type) and the 2-benzopirano-[3,4-g]indole (homolycorine 
type) skeletons, and both types originate from an ortho-para’ phenol oxidative 
coupling (Fig. 4). 
 The biological conversion of cinnamic acid via hydroxylated cinnamic 
acids into the C6-C1 unit of norpluviine has been used in a study of 
hydroxylation mechanisms in higher plants [24]. When [3-3H, β-14C] cinnamic 
acid was fed to Narcissus ‘Texas’ a tritium retention in norpluviine of 28% 
was observed, which is very close to the predicted value resulting from para-
hydroxylation with hydrogen migration and retention. 
 In the conversion of O-methylnorbelladine into lycorine, the labelling 
position [3-3H] on the aromatic ring of L-tyr afterwards appears at C-2 of 
norpluviine, which is formed as an intermediate, the configuration of the 
tritium apparently being β [25]. This tritium is retained in subsequently formed  
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Figure 4. Alkaloids proceeding from an ortho-para’ coupling. 
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lycorine, which means that hydroxylation at C-2 proceeds with an inversion of 
configuration [26] by a mechanism involving an epoxide, with ring opening 
followed by allylic rearrangement of the resulting alcohol (Fig. 5). Supporting 
evidence comes from the incorporation of [2β-3H]caranine into lycorine in 
Zephyranthes candida [27]. However, an hydroxylation of caranine in Clivia 
miniata occuring with retention of configuration was also observed [28]. 
Further, [2α-3H; 11-14C]caranine was incorporated into lycorine with high 
retention of tritium at C-2, indicating that no 2-oxo-compound can be 
implicated as an intermediate. 
 The conversion of the O-methoxyphenol to the methylenedioxy group 
may occur late in the biosynthetic pathway. Tritiated norpluviine is converted 
to tritiated lycorine by Narcissus ‘Deanna Durbin’, which not only 
demonstrates the previously mentioned conversion but also indicates that the 
C-2 hydroxyl group of lycorine is derived by allylic oxidation of either 
norpluviine or caranine [29]. 
 Regarding the conversion of [2β-3H, 8-OMe-14C]pluviine into galanthine, 
in Narcissus ‘King Alfred’, the retention of 79% of the tritium label confirms 
that hydroxylation of C-2 may occur with inversion of configuration [30]. 
 It was considered [31] that another analogous epoxide could give 
narcissidine in the way shown by loss of the pro-S hydrogen from C-11, 
galanthine being a suitable substrate for epoxidation. Labelled [α-14C, β-3H]-
O-methylnorbelladine, when fed to Narcissus ‘Sempre Avanti’ afforded 
galanthine (98% of tritium retention) and narcissidine (46% tritium retention). 
Loss of hydrogen from C-11 of galanthine was therefore stereospecific. In the 
nineties, Kihara et al. [32] isolated a new alkaloid, incartine, from flowers of 
Lycoris incarnata, which could be considered as the biosynthetic intermediate 
of this pathway (Fig. 6). 
 The biological conversion of protocatechuic aldehyde into lycorenine, 
which proceeds via O-methylnorbelladine  and  norpluviine,  first  involves a 
reduction of the aldehyde carbonyl, and afterwards, in the generation of 
lycorenine, oxidation of this same carbon atom. The absolute stereochemistry 
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Figure 5. Biosynthesis of lycorine with inversion of the configuration. 
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Figure 6. Conversion of galanthine to narcissidine via epoxide. 
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Figure 7. Conversion of norpluviine to homolycorine type alkaloids. 
 
of these processes has been elucidated in subsequent experiments [33], and the 
results show that hydrogen addition and removal take place on the re-face of 
the molecules concerned [34], the initially introduced hydrogen being the one 
later removed [35]. It is noteworthy that norpluviine, unlike pluviine, is 
converted in Narcissus ‘King Alfred’ primarily to alkaloids of the 
homolycorine type. Benzylic oxidation at position 6 followed by a ring 
opening forms an amino aldehyde; the formation of hemiacetal and 
subsequent methylation provides lycorenine [30], which after oxidation gives 
homolycorine, as shown in Fig. 7. 
 
1.4.2. Crinine, haemanthamine, tazettine, narciclasine and montanine types 
 
 This group includes the alkaloids derived from 5,10b-ethanophenanthri-
dine (crinine and haemanthamine types), 2-benzopyrano[3,4-c]indole 
(tazettine type), phenanthridine (narciclasine type) and 5,11-
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methanomorphanthridine (montanine type) skeletons, originating from a para-
para’ phenol oxidative coupling (Fig. 8). 
 Results of experiments with labelled crinine, and less conclusively with 
oxovittatine, indicate that the two naturally occurring enantiomeric series, 
represented in Fig. 8 by crinine and vittatine, are not interchangeable in 
Nerine bowdenii [36]. 
 Incorporation of O-methylnorbelladine, labelled in the methoxy carbon 
and also in positions [3,5-3H], into the alkaloid haemanthamine was without 
loss of tritium, half of which was at C-2. Consideration of the possible 
mechanisms involved in relation to tritium retention led to the suggestion that 
the tritium which is expected at C-4 of haemanthamine might not be 
stereospecific [37]. The conversion of O-methylnorbelladine into 
haemanthamine involves loss of the pro-R hydrogen from the C-β of the 
tyramine moiety, as well as a further entry of a hydroxyl group at this site 
[38]. The subsequent benzylic oxidation results in an epimeric mixture that 
even HPLC cannot separate. The epimeric forms were proposed to be 
interchangeable. The biosynthetic conversion of the 5,10b-ethanophenan-
thridine alkaloids to the 2-benzopyrano[3,4-c]indole was demonstrated by 
feeding tritium-labelled alkaloids to Sprekelia formosissima. It was shown that 
this plant converts haemanthamine to haemanthidine/epihaemanthamine and 
subsequently to pretazettine in an essentially irreversible manner [39]. This 
transformation was considered to proceed through an intermediate but it has 
never been detected by spectral methods [40] (Fig. 9). 
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Figure 8. Alkaloids proceeding from a para-para’ coupling. 
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Figure 9. Biosynthesis of pretazettine. 
 
 It has also been proved that the alkaloid narciclasine proceeds from the 
pathway of the biosynthesis of crinine and haemanthamine type alkaloids and 
not through norpluviine and lycorine derivatives. In fact, in view of its structural 
affinity to both haemanthamine and lycorine, narciclasine could be derived by 
either pathway. When O-methylnorbelladine labelled in the methoxy carbon and 
in both protons of position 3 and 5 of the tyramine aromatic ring, was 
administered to Narcissus plants, all four alkaloids incorporated activity. The 
isotopic ratio [3H:14C] for norpluviine and lycorine was, as expected, 50% that 
of the precursor, because of its ortho-para' coupling. On the contrary, in 
haemanthamine the ratio was unchanged. These results show clearly that the 
methoxy group of O-methylnorbelladine is completely retained in the alkaloids 
mentioned, providing a satisfactory internal standard and also, the degree of 
tritium retention is a reliable guide to the direction of phenol coupling. 
Narciclasine showed an isotopic ratio (75%) higher than that of lycorine or 
norpluviine though lower than that of haemanthamine. However, the fact that 
more than 50% of tritium is retained suggests that O-methylnorbelladine is 
incorporated into narciclasine via para-para' phenol oxidative coupling. 
 O-methylnorbelladine and vittatine are implicated as intermediates in the 
biosynthesis of narciclasine [41-43], and the loss of the ethane bridge from the 
latter could occur by a retro-Prins reaction on 11-hydroxyvittatine. Strong 
support for this pathway was obtained by labelling studies. 11-Hydroxyvittatine 
has also been proposed as an intermediate in the biosynthesis of haemanthamine 
and montanine (a 5,11-methanomorphanthridine alkaloid) following the 
observed specific incorporation of vittatine into the two alkaloids in 
Rhodophiala bifida [36] (Fig. 10). 
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Figure 10. Proposed biosynthetic pathways to haemanthamine and montanine. 
 
 Fuganti and Mazza [42,43] concluded that in the late stages of narciclasine 
biosynthesis, the two-carbon bridge is lost from the oxocrinine skeleton, passing 
through intermediates bearing a pseudoaxial hydroxy-group at C-3 position and 
further hydrogen removal from this position does not occur. Noroxomaritidine 
was also implicated in the biosynthesis of narciclasine and further experiments 
[44] showed that it is also a precursor for ismine. 
 The alkaloid ismine has also been shown [45] to be a transformation 
product of the crinine-haemanthamine series. The precursor, oxocrinine 
labelled with tritium in the positions 2 and 4, was administered to Sprekelia 
formosissima plants and the radiactive ismine isolated was shown to be 
specifically labelled at the expected positions. 
 
1.4.3. Galanthamine type 
  
 This type of alkaloids have a dibenzofuran nucleus (galanthamine type) 
and are obtained from a para-ortho’ phenol oxidative coupling. 
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 The initial studies of this pathway suggested that the para-ortho’ coupling 
does not proceed from O-methylnorbelladine but from N,O-dime-
thylnorbelladine to finally give galanthamine [46]. N,O-dimethylnorbelladine 
was first isolated from Pancratium maritimum [47] a species that also contains 
galanthamine. 
 However, the most recent study seems to contradict the evidence set 
forth here. Experiments carried out with application of 13C-labelled                    
O-methylnorbelladine to organs of field grown Leucojum aestivum have 
shown that the biosynthesis of galanthamine involves the phenol oxidative 
coupling of O-methylnorbelladine to a postulated dienone, which undergoes 
spontaneous closure of the ether bridge to yield N-demethylnarwedine, 
giving norgalanthamine after stereoselective reduction. Furthermore, it was 
shown that norgalanthamine is N-methylated to galanthamine in the final 
step of biosynthesis [18] (Fig. 11). In contrast with the literature, N,O-
dimethylnorbelladine was metabolized to a lesser extent in L. aestivum and 
incorporated into galanthamine as well as norgalanthamine at about 1/3 of 
the rate of O-methylnorbelladine. 
 According to Eichhorn et al. [18], narwedine is not the direct precursor 
of galanthamine, and could possibly exist in equilibrium with galanthamine, 
a reaction catalyzed by a hypothetically reversible oxido-reductase. 
 Chlidanthine, by analogy with the known conversion of codeine to 
morphine, might be expected to arise from galanthamine by                    
O-demethylation. This was shown to be true when both galanthamine and 
narwedine, with tritium labels, were incorporated into chlidanthine [48]. 
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Figure 11. Biosynthesis of galanthamine and derivatives. 
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2. NMR studies 
  
 In a discussion of Proton Nuclear Magnetic Resonance (1H NMR) and 
Carbon Nuclear Magnetic Resonance (13C NMR), the most significant 
characteristics of each of Amaryllidaceae alkaloid-type are outlined, 
indicating the keys for their identification.  
 
2.1. Proton nuclear magnetic resonance 
 
 1H NMR spectroscopy gives the most extensive and important 
information about the different types of Amaryllidaceae alkaloids. In the last 
25 years, the routine use of 2D NMR techniques has facilitated the structural 
assignments and the settling of their stereochemistry.  
 
2.1.1. Lycorine type 
  
 This group has been subjected to several 1H NMR studies and lycorine, as 
well as its main derivatives, has been completely assigned. The general 
characteristics of the 1H NMR spectra are: 
 
a. Two singlets for the para-oriented aromatic protons, together with a 
unique olefinic proton. 
b. Two doublets as an AB system corresponding to the benzylic protons of       
C- 6. The deshielding observed in the β-protons of positions 6 and 12 in 
relation to their α-homologues is due to the effect of the cis-lone pair of 
the nitrogen atom.  
c. Like almost all other lycorine type examples, the alkaloids isolated from 
the Narcissus genus show a trans B/C ring junction, the coupling constant 
being J4a,10b~11 Hz. Only kirkine shows a cis B/C ring junction, with a 
smaller coupling constant J4a,10b 8 Hz. 
   
 In the plant, the alkaloid lycorine is particularly vulnerable to oxidation 
processes, giving several ring-C aromatized products. 
 
2.1.2. Homolycorine type 
  
 This group includes lactone, hemiacetal or the more unusual cyclic ether 
alkaloids. The general traits for this type of compounds could be summarized 
as follows: 
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a. Two singlets for the para-oriented aromatic protons. In lactone alkaloids, 
the deshielding of H-7 is caused by the peri-carbonyl group.  
b. The hemiacetal alkaloids always show the substituent at C-6 in                    
α-disposition. 
c. The majority of compounds belong to a single enantiomeric series 
containing a cis B/C ring junction, which is congruent with the small size 
of the coupling constant J1,10b. In the Narcissus genus no exception to this 
rule has been observed. 
d. The large coupling constant between H-4a and H-10b (J4a,10b~10 Hz) is 
only consistent with a trans-diaxial relationship. 
e. In general, ring C presents a vinylic proton. If position 2 is substituted by 
an OH, OMe or OAc group, it always displays an α-disposition. 
f. The singlet corresponding to the N-methyl group is in the range of δ 2.0-
2.2 ppm, its absence being very unusual. 
g. The H-12α is more deshielded than H-12β as a consequence of the cis-
lone pair of the nitrogen atom. 
  
 Homolycorine type alkaloids with a saturated ring C have been studied by 
Jeff and co-workers [49]. They describe empirical correlations of N-methyl 
chemical shifts with stereochemical assignments of the B/C and C/D ring 
junction. 
 
2.1.3. Haemanthamine and crinine types 
  
 The absolute configuration of these alkaloids is determined through the 
circular dichroism spectrum. The alkaloids of the Narcissus genus are 
exclusively of the haemanthamine type, while in genera such as Brunsvigia, 
Boophane etc., the crinine type alkaloids are predominant. It is also 
noteworthy that the alkaloids isolated from the Narcissus genus do not show 
additional substitutions in the aromatic ring apart from those of C-8 and         
C-9. On the contrary, in the genera where crinine type alkaloids 
predominate, the presence of compounds with a methoxy substituent at C-7 
is quite common. Thus, haemanthamine type alkaloids show the following 
characteristics: 
 
a. Two singlets for the para-oriented aromatic protons, although of course 
only one for crinane type alkaloids substituted at C-7. 
b. Using CDCl3 as the solvent, the magnitude of the coupling constants 
between each olefinic proton (H-1 and H-2) and H-3 gives information 
about the configuration of the C-3 substituent. Thus, in those alkaloids in 
which the two-carbon bridge (C-11 and C-12) is cis to the substituent at 
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C-3, H-1 shows an allylic coupling with H-3 (J1,3~1-2 Hz) and H-2 shows 
a smaller coupling with H-3 (J2,3~0-1.5 Hz), as occurs in crinamine. On 
the contrary, in the corresponding C-3 epimeric series, e.g. 
haemanthamine, a larger coupling between H-2 and H-3 (J2,3 5 Hz) is 
shown, the coupling between H-1 and H-3 not being detectable. This rule 
is also applicable to the crinane type alklaoids. 
c. In the haemanthamine series there is frequently an additional W coupling 
of H-2 with the equatorial H-4β, while the proton H-4α shows a large 
coupling with H-4a (J4α,4a~13 Hz) due to their trans-diaxial disposition. 
The same is applicable in the crinane series. 
d. Two doublets for an AB system corresponding to the benzylic protons of 
position C-6.  
e. The pairs of alkaloids with a hydroxy substituent at C-6, like papyramine/  
6-epipapyramine, haemanthidine/6-epihaemanthidine etc, appear as a 
mixture of epimers not separable even by HPLC. 
f. Also in relation with position C-6, it is interesting to note that ismine, a 
catabolic product from the haemanthamine series, shows a restricted 
rotation around the biarylic bond, which makes the methylenic protons at 
the benzylic position magnetically non-equivalent. 
 
2.1.4. Tazettine type  
  
 Although tazettine is one of the most widely reported alkaloids in the 
Amaryllidaceae family, it was found to be an extraction artifact from 
pretazettine [50]. 
 The presence of an N-methyl group (2.4-2.5 ppm) in tazettine type 
alkaloids immediately distinguishes them from the haemanthamine or crinine 
types, from which they proceed biosynthetically. Moreover, the 1H NMR 
spectrum always shows the signal corresponding to the methylenedioxy 
group. 
 
2.1.5. Montanine type 
  
 The absolute configuration of Montanine-type alkaloids is determined 
through the circular dichroism spectrum. Their 1H NMR data are very similar 
to those of alkaloids with a lycorine skeleton, but Montanine-type alkaloids 
can be distinguished by the analysis of a COSY spectrum. The signals 
attributable to the H-4 hydrogens (the most upfield signals) show correlation 
with those corresponding to H-3 and H-4a, while in a lycorine skeleton the 
most upfield signals correspond to the H-11 hydrogens. 
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2.1.6. Narciclasine type 
  
 The narciclasine-type alkaloids present the highest degree of oxidation. 
The absolute configuration of the most studied alkaloid of this group 
pancratistatin, was determined by X-ray diffraction [51]. The main 1H NMR 
characteristics of the narciclasine-type alkaloids are: 
 
a. The only aromatic hydrogen appears as a singlet with a chemical shift 
higher than 7 ppm. 
b. Those alkaloids with a hydrogenated double bond C-1/C-10b possess a 
trans stereochemistry for the B-C ring junction and, consequently, a large 
coupling constant value for J4a-10b. 
c. The hydrogen attached to the nitrogen atom appears as a broad singlet 
with a chemical shift around 5 ppm, which disappears on the addition of 
D2O. 
 
2.1.7. Galanthamine type 
  
 Among the Amaryllidaceae alkaloids, only the galanthamine type shows 
an ortho-coupling constant between both aromatic protons of ring A. The 
general characteristics of their 1H NMR spectra are: 
 
a. Two doublets for the two ortho-oriented aromatic protons with a coupling 
constant of J7,8~8 Hz. 
b. The assignment of the substituent stereochemistry at C-3 is made in 
relation with the coupling constants of the olefinic protons H-4 and H-4a. 
When coupling constant J3,4 is about 5 Hz, the substituent is pseudoaxial, 
while if it is ~0 Hz this indicates that the substituent at C-3 is pseudo-
equatorial. 
c. Two doublets corresponding to the AB system of the C-6 benzylic 
protons. 
d. The existence of the furan ring results in a deshielding effect in H-1. 
e. This type of alkaloids often shows an N-methyl group but occasionally an 
N-formyl group has been reported.  
 
2.2. Carbon13 nuclear magnetic resonance 
  
 13C NMR spectroscopy has been extensively used for determining the 
carbon framework of Amaryllidaceae alkaloids, and there are several major 
contributions [52-54]. The assignments are made on the basis of chemical 
shifts and multiplicities of the signals (by DEPT experiment). The use of 2D 
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NMR techniques such as HMQC and HMBC allow the assignments to be 
corroborated.  
 The 13C NMR spectra of Amaryllidaceae alkaloids can be divided in two 
regions. The low-field region (>90 ppm) contains signals of the carbonyl 
group, the olefinic and aromatic carbons as well as that of the methylenedioxy 
group. The other signals corresponding to the saturated carbon resonances are 
found in the high-field region, the N-methyl being the only characteristic 
group, easily recognizable by a quartet signal between 40-46 ppm. 
 The effect of the substituent (OH, OMe, OAc) on the carbon resonances is 
of considerable importance in localizing the position of the functional groups.  
 The analysis of the spectra allows conclusions to be drawn about the 
following aspects: 
 
- The number of methine olefinic carbons.  
- The presence and nature of the nitrogen substituent.  
- The existence of a lactonic carbonyl group. 
- The presence of a quaternary carbon signal assignable to C-10b in the 
chemical shift range of 42-50 ppm. 
 
3. Biological and pharmacological activities 
  
 This section covers the pharmacological and/or biological properties of 
the most representative Amaryllidaceae alkaloids. Until now only galathamine 
is being marketed, but the significant activities of other alkaloids in the family 
demonstrated in recent years could favour their therapeutic use in the near 
future.  
 
3.1. Lycorine type 
  
 The most characteristic and common Amaryllidaceae alkaloid is lycorine, 
reported to be a powerful inhibitor of ascorbic acid (L-Asc) biosynthesis 
[55,56], and thus a useful tool in studying Asc-dependent metabolic reactions 
in L-Asc-synthesising organisms [57,58]. Specifically, lycorine is a powerful 
inhibitor of the activity of L-galactono-γ-lactone dehydrogenase, the terminal 
enzyme of L-Asc biosynthesis [59-62], which is thought to be localised in the 
mitochondrial membrane [63,64]. Galanthine also has a high capacity to 
inhibit ascorbic acid biosynthesis [56]. 
 Lycorine is a powerful inhibitor of cell growth, cell division and 
organogenesis in higher plants, algae, and yeasts, inhibiting the cell cycle 
during interphase, which seems to be related with the L-Asc levels [57,65-69]. 
In plants, it also inhibits cyanide-insensitive respiration, peroxidase activity 
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and protein synthesis [70-72]. The effects of lycorine on L-Asc biosynthesis 
have been reported to occur at concentrations below those at which protein 
synthesis is affected, but it seems difficult to completely rule out non-specific 
effects of this alkaloid since it has been reported that, at least in yeasts, 
lycorine is able to interact directly with mitocondrial DNA. Thus, differing 
sensitivity to the alkaloid among cells devoid of mitochondrial DNA (rho0) 
and cells with mitochondrial DNA either rho+ or rho- has been found in yeasts 
[59,67,73,74], rho0 cells being resistant to high concentrations of the drug 
[69,75-77]. Some strains can even adapt to the presence of lycorine, because 
they are able to degrade the alkaloid and use its biotransformation products as 
growth stimulating factors [77]. In contrast, lycorine-1-O-β-D-glucoside 
promotes cell growth, seed germination, and rate of development of root and 
root hairs in higher plants. The glucosyloxy derivatives of lycorine and 
pseudolycorine and their aglicones form stable complexes with phytosterols 
and also with divalent metal ions and are able to translocate them from the 
rhizosphere to the aerial part [78]. Palmilycorine and some acylglucosyloxy 
conjugates of lycorine, in turn, are frequently encountered among the 
phytosterols exhibiting membrane-stabilizing action. Plants also use lycorine-
1-O-β-D-glucoside and acylglucosyloxy conjugates of lycorine to recognize 
and reject microorganisms and parasites [79]. 
 The antitumor activity of lycorine in animals [80,81] has been 
demonstrated by the inhibition of in vivo and in vitro growth of diverse tumor 
cells, such as BL6 mouse melanoma, Lewis lung carcinoma, murine ascite or 
HeLa cells [3,79,82-86]. It induces flat morphology in K-ras-NRK cells 
(transformed fibroblasts) [87], and reduces the cellular activity in femoral 
bone marrow tissue that results in granulocytic leucopenia and a decrease in 
the number of erythrocytes. This alkaloid’s mechanism of action is thought to 
be through inhibition of protein synthesis at the ribosomal level, even though 
the cytotoxic effects of calprotectin can also be suppressed using lycorine 
[80,81,88-90]. Lycorine also inhibits murine macrophage production of 
Tumor Necrosis Factor alpha (TNF-α) [91], and shows inhibitory effects on 
nitric oxide production and induction of inducible nitric oxide synthase (NOS) 
in lipopolysaccharide-activated macrophages [92]. The molecular mechanism 
of lycorine against leukaemia (human cell line HL-60) shows that it can 
suppress cell growth and reduce cell survival by arresting the cell cycle at the 
G2/M phase and inducing apoptosis of tumor cells [93]. Recent studies show 
that the TNF-α signal transduction pathway and p21-mediated cell-cycle 
inhibition  are involved in the apoptosis of HL-60 cells induced by lycorine 
[94]. The effects of lycorine on the human multiple myeloma cell line KM3, 
and the possible mechanisms of these effects have also been studied [95]. The 
growth rates of the KM3 cells exposed to lycorine clearly slowed down. Cell 
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fluorescent apoptotic morphological changes, DNA degradation fragments, 
and a sub-G1 peak were detected, indicating the occurrence of cell apoptosis 
after lycorine treatment. Furthermore, the release of mitochondrial 
cytochrome c, the augmentation of Bas with the attenuation of Bcl-2, and the 
activation of Caspase-9, -8, and -3 were also observed, suggesting that the 
mitochondrial pathway and the death acceptor pathway were involved. The 
results also showed that lycorine was able to block the cell cycle at the G0/G1 
phase through the downregulation of both cyclin D1 and CDK4. In short, 
lycorine can suppress the proliferation of KM3 cells and cell survival by 
arresting cell cycle progression as well as inducing cell apoptosis [96]. A 
recent paper describes the preparation of a mini-library comprised of synthetic 
and natural lycorane alkaloids and the investigation of apoptosis-inducing 
activity in human leukemia (Jurkat) cells. Further insights into the nature of 
this apoptosis-inducing pharmacophore are described, including the 
requirement of both free hydroxyl groups in ring-C [97]. Another recent study 
describes the induction of apoptosis in human leukemia cells by lycorine via 
an intrinsic mitochondria pathway, causing a rapid turnover of protein level of 
Mcl-1 before Caspases activation. Pronounced apoptosis accompanied by the 
down-regulation of Mcl-1 was also observed in blasts from patients with acute 
myeloid leukemia. Lycorine also displays pronounced cell growth inhibitory 
activities against both parental and multidrug resistant L5178 mouse 
lymphoma cell lines, but is almost inactive in inhibiting the glycoprotein 
responsible for the efflux-pump activity of tumor cells. Assays for interactions 
with tRNA revealed that the antiproliferative effects of lycorine result from 
their complex formation with tRNA [98]. Interaction of lycorine, 
pseudolycorine and 2-O-acetylpseudo-lycorine with DNA has been observed 
[99,100]. Most of the alkaloids that showed promising antiproliferative 
activities have also proved to be efficient apoptosis inducers [14].  
 Some other alkaloids of this series, such as caranine, galanthine, 
pseudolycorine and 2-O-acetylpseudolycorine, are also active against a variety 
of tumor cells [84,101,102]. Pseudolycorine inhibits the protein synthesis in 
tumor cells at the step of peptide bond formation, but it has a different binding 
site than lycorine [89,103]. Ungeremine, a natural metabolite of lycorine, is 
responsible, at least partially, for the growth-inhibitory and cytotoxic effects 
of lycorine, being active against leukemia [104,105]. Lycorine-1-O-β-D-
glucoside, in turn, has the reverse effect of lycorine, and may produce 
mitogenic activity in animal cells [106]. 
 A mini-panel of semi-synthetic analogs of lycorine was screened for 
cytochrome P450 3A4 (CYP3A4) inhibitory activity, the most potent of which 
(1-O-acetyl-2-O-tert-butyldimethylsilyllycorine) exhibited inhibition at a 
concentration as low as 0.21 μM. Elements of this unraveled novel 
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pharmacophore include bulky lipophilic substitution at C-2 in conjunction 
with a small hydrogen donor/acceptor bond at C-1, or bulky electron-rich 
substitution at C-1 in conjunction with a vicinal hydrogen donor/acceptor 
bond [107]. Two semisynthetic silylated lycorane analogs, accesed via a 
chemoselective silylation strategy from lycorine exhibited low micromolar 
activities [108]. 
 Lycorine and pseudolycorine exert antiviral effects on several RNA and 
DNA-containing viruses [109]. Antiviral activity has been observed in tests with 
flaviviruses, and to a slightly lesser degree, bunyaviruses. Lycorine and 
pseudolycorine also show inhibitory activity against the Punta Toro and Rift 
Valley fever viruses, but with low selectivity [110,111]. Lycorine, in turn, acts 
as an anti-SARS-CoV (Severe Acute Respiratory Syndrome-associated 
Coronavirus) and shows pronounced activity against poliomyelitis, coxsackie 
and herpes type 1 [3,112]. It possesses high antiretroviral activity accompanied 
by low therapeutic indices [113]. The relationship between its structure and the 
mechanism of activity has been studied in the Herpes simplex virus, suggesting 
that alkaloids that may eventually prove to be antiviral agents have a 
hexahydroindole ring with two functional hydroxyl groups [114]. The activity 
was found to be due to the inhibition of multiplication, and not to the direct 
inactivation of extracellular viruses, and the mechanism of the antiviral effect 
was partially explained as a blocking of viral DNA polymerase activity 
[109,115-117]. 
 Lycorine has appreciable inhibitory activity against acetylcholinesterase 
[118]. Cholinesterase activity appears to be associated with the two free 
hydroxyl groups present in some of the alkaloids of this structural type 
[119]. The higher acetylcholinesterase inhibitory activity of assoanine and 
oxoassoanine with respect to the other lycorine-type alkaloids could be 
explained by an aromatic ring C, which gives a certain planarity to those 
molecules [120]. Another alkaloid, galanthine, exhibits powerful cholinergic 
activity and has therefore attracted much interest in the treatment of 
myasthenia gravis, myopathy and diseases of the central nervous system 
[121]. Caranine, pseudolycorine, ungiminorine, and in particular, 
ungeremine, also show an inhibitory effect on acetylcholinesterase 
[120,122,123]. Recently, the synthesis of differentially functionalized 
analogs of lycorine, accessed via a concise chemoselective silylation 
strategy, has allowed two of the most potent inhibitors of 
acetylcholinesterase to be described. Important elements of this novel 
pharmacophore were elucidated through SAR studies [94]. 
 Lycorine is analgesic, more so than aspirin, and hypotensive [124,125], as 
are caranine and galanthine. The analgesic activity exhibited by the 
Amaryllidaceae alkaloids is attributed to their similarity with the morphine 
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and codeine skeletons. Lycorine also has antiarrhythmic action, and lycorine 
hydrochloride is a strong broncholytic [126]. In fact, lycorine shows a relaxant 
effect on an isolated epinephrine-precontracted pulmonary artery and 
increases contractility and the rate of an isolated perfused heart. These effects 
are mediated by stimulation of β-adrenergic receptors [127]. 
 Lycorine also has a strong inhibitory effect on parasite (Encephalitozoon 
intestinalis) development [128] and antifungal activity against Candida 
albicans [129]. Recently, several lycorine derivatives were examined for their 
activity against Trypanosoma brucei and Plasmodium falciparum. Among 
them, 2-O-acetyllycorine showed the most potent activity against parasitic          
T. brucei, while 1-O-(3R)hydroxybutanoyllycorine, 1,2-di-O-butanoyllycorine, 
and 1-O-propanoyllycorine showed significant activity against P. falciparum 
in an in vitro experiment [130], although the antimalarial activity of lycorine 
was already known [131-133]. Galanthine, in turn, shows mild in vitro activity 
against Tripanosoma brucei rhodesiense and Plasmodium falciparum [134]. 
Additionally, lycorine has antifeedant [135], emetic [136], anti-inflammatory 
[137], antiplatelet [138] as well as antifertility [125] activities. 
 
3.2. Homolycorine type 
  
 It is reported that some alkaloids of this series, such as homolycorine,                 
8-O-demethylhomolycorine, dubiusine, 9-O-demethyl-2α-hydroxyhomoly-corine, 
hippeastrine, lycorenine or O-methyllycorenine present cytotoxic effects against 
non-tumoral fibroblastic LMTK cells [84], also being moderately active in 
inhibiting the in vivo and in vitro growth of a variety of tumor cells, such as Molt 
4 lymphoma, HepG2 human hepatoma, LNCaP human prostate cancer or HT 
[84,125,139]. Dubiusine, lycorenine, 8-O-demethylhomolycorine and 9-O-
demethyl-2α-hydroxyhomolycorine also show DNA binding activity comparable 
to that of vinblastine [99]. Homolycorine possesses high antiretroviral activity, 
accompanied by low therapeutic indices [113]. Hippeastrine, in turn, displays 
antiviral activity against Herpes simplex type 1 [114].  
 Dubiusine, homolycorine, 8-O-demethylhomolycorine and lycorenine 
have a hypotensive effect on the arterial pressure of normatensive rats [140]. 
Lycorenine also shows a vasodepressor action ascribed to the maintenance of 
its α-adrenergic blocking action, and produces bradycardia by modifying 
vagal activity [141]. Another feature of lycorenine is its analgesic activity [3]. 
 Homolycorine and masonine are other inductors of delayed 
hypersensitivity in animals [142]. Hippeastrine, in turn, shows antifungal 
activity against Candida albicans and it also possesses a weak insect 
antifeedant activity [129]. 
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3.3. Haemanthamine and crinine types 
  
 Haemanthamine, haemanthidine, crinamine, maritidine and papyramine 
display pronounced cell growth inhibitory activities against a variety of tumor 
cells, such as Rauscher viral leukaemia, Molt 4 lymphoma, BL6 mouse 
melanoma, HepG2 human hepatoma, HeLa, LNCaP human prostate cancer or 
HT [82-84,88,139,143,144]. Some of these alkaloids, namely crinamine, 
haemanthamine and papyramine, also present a cytotoxic effect against non-
tumoral fibroblastic LMTK cells [84]. The mechanism of action of 
haemanthamine is thought to be through inhibition of protein synthesis, 
blocking the peptide bond formation step on the peptidyl transferase centre of 
the 60S ribosomal subunit [89,103]. Haemanthamine and haemanthidine also 
display the same pronounced cell growth inhibitory activities against both 
parental and multidrug resistant L5178 mouse lymphoma cell lines as 
described above for lycorine [98]. Crinamine, in turn, shows inhibitory effects 
on nitric oxide (NO) production and induction of inducible nitric oxide 
synthase (NOS) in lipopolysaccharide-activated macrophages [92]. Crinamine 
and haemanthamine are potent inducers of apoptosis in tumor cells at 
micromolecular concentrations [145]. The pharmacophoric elements are the 
alpha-C-2 bridge as well as a small substituent (H, or OH) at C-11. Studies 
have also shown that α- or β-methoxy or the hydroxyl H-bond acceptor are all 
tolerated at C-3, and that a C-1/C-2 double bond modulates, but is not a 
requirement, for apoptosis-inducing activity [146].  
 The antimalarial activity against strains of chloroquine-sensitive 
Plasmodium falciparum observed in haemanthamine and haemanthidine can 
be attributed to the methylenedioxybenzene part of the molecule and the 
terciary nitrogen without methyl [131]. Crinamine also exhibits moderate 
antimalarial activity [132,147]. Haemanthidine also works in vitro against 
Trypanosoma brucei rhodesiense and to a lesser extend against Trypanosoma 
cruzi [134]. Vittatine has antibacterial activity against the Gram-positive 
Staphylococcus aureus and the Gram-negative Escherichia coli [129], and the 
alkaloid crinamine shows strong activity against Bacillus subtilis and 
Staphylococcus aureus [148].  
 Like lycorine, haemanthidine has stronger analgesic and                     
anti-inflammatory activity than aspirin [118,137], and vittatine has been    
found to potentiate the analgesic effect of morphine [149]. Moreover, some 
alkaloids of this series, such as haemanthamine or papyramine have a 
hypotensive effect [140,150], and haemanthamine strong antiretroviral 
activity [113]. 
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3.4. Tazettine type 
  
 Tazettine is mildly active against certain tumor cell lines [88,139,151], 
with a slight cytotoxicity when tested on fibroblastic LMTK cell lines [84]. 
Tazettine also displays weak hypotensive and antimalarial activities and 
interacts with DNA [99,138,140]. Its chemically labile precursor, pretazettine, 
is far more interesting owing to its antiviral and anticancer activities. In fact, 
when pretazettine is stereochemically rearranged to tazettine, the biological 
activity of the precursor is to a large extent inactivated [152,153].  
 Pretazettine shows cytotoxicity against fibroblastic LMTK cell lines and 
inhibits HeLa cell growth, being therapeutically effective against advanced 
Rauscher leukaemia, Ehrlich ascites carcinoma, spontaneous AKR 
lymphocytic leukaemia and Lewis lung carcinoma [151,154-159]. It is one of 
the most active of the Amaryllidaceae alkaloids against Molt4 lymphoid cells 
[84], and is used in combination with DNA-binding and alkylating agents in 
treating the Rauscher leukaemia virus [151,154]. In fact, pretazettine strongly 
inhibits the activity of reverse transcriptase from various oncogenic viruses by 
binding to the enzyme [3]. It inhibits both the growth of the Rauscher virus 
and cellular protein synthesis in eukaryotic cells by a mechanism that does not 
affect DNA and RNA synthesis, even though it has a pronounced DNA 
binding activity [88,89,99,101,111,156,160]. Pretazettine on human MDR1-
gene-transfected L5158 mouse lymphoma significantly increased the 
intracellular concentration of Rh-123 and enhanced the antiproliferative 
activity of doxorubicin in the L5178 MDR cell line [161]. This alkaloid has 
also been shown to be active against selected RNA-containing flavoviruses 
(Japanese encephalitis, yellow fewer and dengue) and bunyaviruses (Punta 
Toro and Rift Valley fever) in organ culture [111]. It also possesses 
pronounced activity against Herpes simplex type 1 virus [114]. This activity 
may reflect a general ability to inhibit protein synthesis during viral 
replication [162]. 
 
3.5. Narciclasine type 
  
 Narciclasine, an antimitotic and antitumoral alkaloid [163], affects cell 
division at the metaphase stage and inhibits protein synthesis in eukaryotic 
ribosomes by directly interacting with the 60s subunit and inhibiting peptide 
bond formation by preventing binding of the 3' terminal end of the donor 
substrate to the peptidyl transferase center [89,103,164-166]. It also retards 
DNA synthesis [167] and inhibits calprotectin-induced cytotoxicity at a more 
than 10-fold lower concentration than lycorine [90]. The peculiar effects of 
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narciclasine seem to arise from the functional groups and conformational 
freedom of its C-ring [168], with the 7-hydroxyl group believed to be 
important in its biological activity [169]. This alkaloid, related to 
pancratistatin [167], is one of the most important antineoplastic 
Amaryllidaceae alkaloids [80] and shows some promise as an anticancer 
agent. It inhibits HeLa cell growth, has antileukaemic properties and is active 
against a variety of tumor cells, such as human and murine lymphocytic 
leukaemia, larynx and cervix carcinomas and Ehrlich tumor cells 
[115,167,170-172]. One hemisynthetic derivative of narciclasine 
demonstrated higher in vivo antitumor activity in human orthotopic glioma 
models in mice than narciclasine in nontoxic doses [173], by both the i.v and 
oral routes. No effect has been observed on solid tumors. Narciclasine-4-O-β-
D-glucopiranoside shows a very similar cytotoxic and antitumoral activity to 
narciclasine [174]. The anticancer activity and preclinical studies of 
narciclasine and its congeners has been gathered by Kornienko and Evidente 
in a recent review [175]. Melanomas display poor response rates to adjuvant 
therapies because of their intrinsic resistance to proapoptotic stimuli. Such 
resistance can be overcome, at least partly, through the targeting of the eEF1A 
elongation factor with narciclasine [176]. This alkaloid directly binds to 
human recombinant and yeast-purified eEF1A in a nanomolar range, but not 
to actin or elongation factor 2. Thus, eEF1A is a potential target to combat 
melanomas regardless of their apoptosis-sensitivity, which has renewed 
interest in the pleiotropic cytostatic activity of narciclasine.  Apoptosis in 
Jurkat cells was triggered by narciclasine, narciclasine tetraacetate, C-10b-R-
hydroxypancratistatin, cis-dihydronarciclasine and trans-dihydronarciclasine 
[177]. 
 The effect of pancratistatin treatment on cancerous and normal cells has 
also been reported [178]. The results indicated that pancratistatin selectively 
induced apoptosis in cancer cells, and the mitochondria may be the site of 
action. To further explore the structure-activity relationship of pancratistatin-
related compounds, the anticancer efficacy and specificity of two related natural 
alkaloids were investigated. Both of these compounds lack the polyhydroxylated 
lycorane element of pancratistatin, instead having a methoxy-substituted crinane 
skeleton. These results indicated that the phenanthridone skeleton in natural 
Amaryllidaceae alkaloids may be a significant common element for selectivity 
against cancer cells. The synergy of pancratistatin and tamoxifen on breast 
cancer cells in inducing apoptosis by targeting mitochondria has been also 
reported [179]. The 3,4-O-cyclic phosphate salt of pancratistatin is a novel, 
water soluble synthetic derivative of pancratistatin that in vivo caused 
statistically significant tumor growth delays at its maximum-tolerated dose. 
Significant vascular shutdown and tumor necrosis were also observed [180], 
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offering a way forward for improved clinical treatment by greatly enhancing 
solubility without loss of antitumor activity. 
 Narciclasine has a prophylactic effect on the adjuvant arthritis model in rats, 
significantly suppressing the degree of swelling of adjuvant-treated as well as 
untreated feet [90]. This alkaloid is also active against Corynebacterium 
fascians, inhibits the pathogenic yeast Cryptococcus neoformans, and 
modifications like 2,3,4,7-tetra-O-acetylnarciclasine inhibit the growth of the 
pathogenic bacterium Neisseria gonorrhoeae [181]. Antiviral activity has been 
observed against RNA-containing flaviviruses and bunyaviruses [111]. 
 At the plant level, narciclasine is a potent inhibitor, showing a broad 
range of effects, including the ability to inhibit seed germination and seedling 
growth of some plants in a dose-dependent manner, interacting with hormones 
in some physiological responses [182]. Thus, indole-3-acetic acid cannot 
overcome the inhibition of elongation of wheat coleoptile sections caused by 
narciclasine. Additionally, narciclasine suppresses the gibberellin-induced         
α-amylase production in barley seeds and cytokinin-induced expansion and 
greening of excised radish cotyledons [183]. Like lycorine, narciclasine also 
inhibits ascorbic acid biosynthesis [184]. Narciclasine, present in daffodil 
mucilage, can delay tepal senescence in cut Iris flowers by attenuation of 
protease activity, which, in turn, is apparently related with the inhibition of the 
protein synthesis involved in senescence [185]. At the organelle level, 
narciclasine inhibits both isocitrate lyase (ICL) activity in glyoxysomes and 
hydroxypyruvate reductase (HPR) activity in peroxisomes. It also blocks the 
formation of chloroplasts, markedly reducing the chlorophyll content of light-
grown wheat seedlings, probably due to the inhibition of the formation of           
5-aminolevulinic acid, an essential chlorophyll precursor [186]. The formation 
of light harvesting chlorophyll a/b binding protein (LHCP) is also inhibited by 
this alkaloid [187]. 
 Some alkaloids of this series, such as trisphaeridine, possess high 
antiretroviral activities, accompanied by low therapeutic indices [113]. 
Ismine, in turn, shows a significant hypotensive effect on the arterial pressure 
of normotensive rats [140] and is cytotoxic against Molt 4 lymphoid and 
LMTK fibroblastic cell lines [84]. 
 
3.6. Montanine type 
  
 There is little information about the montanine type alkaloids, only some 
data about pancracine, which shows antibacterial activity against 
Staphylococcus aureus and Pseudomonas aeruginosa [129], as well as weak 
activity against Trypanosoma brucei rhodesiense, T. cruzi and Plasmodium 
falciparum [188]. Montanine inhibited, in a dose-dependent manner, more 
Jaume Bastida et al.  90
than 50% of the enzyme acetylcholinesterase at 1 mM concentration. With the 
concentrations 500 μM and 100 μM, 30-45% of inhibition was detected [189].  
 
3.7. Galanthamine type 
  
 Galanthamine, originally isolated from Galanthus nivalis L. in the 1940s, 
is a long-acting, selective, reversible and competitive inhibitor of 
acetylcholinesterase. This enzyme is responsible for the degradation of 
acetylcholine at the neuromuscular junction, in peripheral and central 
cholinergic synapses and in parasympathetic target organs [190-192]. 
Galanthamine has the ability to cross the blood-brain barrier and act within the 
central nervous system [193,194]. It binds at the base of the active site gorge 
of acetylcholinesterase, interacting with both the choline-binding site and the 
acyl-binding pocket, having a number of moderate-to-weak interactions with 
the protein [195-197]. In addition, galanthamine stimulates pre- and 
postsynaptic nicotinic receptors which can, in turn, increase the release of 
neurotransmitters, thus directly stimulating neuronal function [192,198]. It is 
also suggested that the stimulation of nicotinic receptors protects against 
apoptosis induced by β-amyloid toxicity [192,199,200]. Its dual mode of 
action [195], coupled with the evidence that galanthamine has reduced side 
effects, make it a promising candidate for the treatment of nervous diseases, 
paralysis syndrome, schizophrenia and other forms of dementia, as well as 
Alzheimer's disease [192,195,196]. 
 Other significant pharmacological actions of Galanthamine include an 
ability to amplify the nerve-muscle transfer [3], affecting membrane ionic 
processes [201]. It is also known to cause bradycardia or atrioventricular 
conduction disturbances [150], has long been used as a reversal agent in 
anaesthetic practice [18], inhibits traumatic shock and has been patented for 
use in the treatment of nicotine dependence. Besides this, galanthamine acts as 
a mild analeptic, shows an analgesic power as strong as morphine, 
compensates for the effects of opiates on respiration, relieves jet lag, fatigue 
syndrome, male impotence and alcohol dependence, and when applied in eye 
drops, reduces the intraocular pressure [3,202-204]. It also acts as a 
hypotensive and has a weak antimalarial activity [138,140]. 
 At present, Alzheimer's disease cannot be prevented or cured, so the 
symptomatic relief offered by AChEI therapy is the only approved therapeutic 
option. Due to the relative lack of alternative treatment, galanthamine is a 
reasonable approximation of the ideal concept of symptomatic Alzheimer's 
disease therapy [191,205]. Galanthamine hydrobromide (a third-generation 
cholinesterase inhibitor used against Alzheimer’s disease) offers superior 
pharmacological profiles and increased tolerance compared to the original 
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acetylcholinesterase inhibitors, physostigmine or tacrine [193,206-209]. 
Galanthamine is effective and well tolerated, resulting in short-term 
improvements in cognition, function and daily life activities in patients with 
mild to moderate symptoms [198,210,211]. However, there is doubt about its 
long-term benefits [212] since persistent elevation of acetylcholine beyond 6 
months may lead to over-stimulation of both nicotinic and muscarinic 
acetylcholine receptors, the former causing receptor desensitisation and the 
latter potentially causing an increased frequency of cholinergic side effects 
[192,198,213]. The safety profile of galanthamine as well as its clinical 
effectiveness will only be demonstrated after large-scale clinical trials         
[213-215].  
 The development of galanthamine into a widely used Alzheimer’s drug 
can be divided into three main periods: 1- the early development in Eastern 
Europe for its use in the treatment of poliomyelitis; 2- the pre-clinical 
development in the 1980s; 3- the clinical development in the 1990s [213]. 
Galanthamine hydrobromide was first used by Bulgarian and Russian 
researchers in the 1950s and exploited for a variety of clinical purposes. It has 
been used clinically for postsurgery reversal of tubocurarine-induced muscle 
relaxation and for treating post-polio paralysis, myasthenia gravis and other 
neuromuscular diseases, as well as traumatic brain injuries [216,217]. As early 
as 1972, Soviet researchers demonstrated that galanthamine could reverse 
scopolamine-induced amnesia in mice, a finding that was demonstrated in 
man 4 years later. However, this compound was not applied to Alzheimer's 
disease until 1986, long after the widely accepted cholinergic hypothesis had 
been first postulated, when researchers in Western Europe switched their 
attention to galanthamine due to its ability to penetrate the blood-brain barrier 
and specifically to augment the central cholinergic function [213,218]. This 
led to clinical trials of galanthamine in the treatment of Alzheimer's disease. 
In 1996, Sanochemia Pharmazeutika in Austria first launched galanthamine as 
‘Nivalin®’, but its strictly limited availability meant the international 
pharmaceutical community adopted a cautions approach [18,194], until 
Sanochemia Pharmazeutika developed a method to synthetically produce the 
compound in 1997 [219]. Later, galanthamine was co-developed by Shire 
Pharmaceuticals (Great Britain) and the Janssen Research Foundation 
(Belgium), who have launched galanthamine as ‘Reminyl®’ in many countries 
[192,213]. This renewed interest is reflected in the increasing number of 
scientific reviews dealing exclusively with galanthamine and its derivatives 
[220-223]. 
 Sanguinine has a more potent acetylcholinesterase inhibitory activity than 
galanthamine due to an extra hydroxyl group available for potential 
interaction with acetylcholinesterase [120]. Sanguinine, in turn, is 10-fold 
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more selective than galanthamine for acetylcholinesterase (AChE) vs. 
butyrylcholinesterase (BuChE) [224]. The lack of AChE inhibitory activity of 
lycoramine and epinorlycoramine could be due to the occurrence of a double 
bond in ring C, which does not allow these compounds to have the same 
spatial configuration as the active alkaloids of this series [120]. 
   Narwedine, the biogenic precursor of galanthamine, has been studied as a 
respiratory stimulator. It increases the amplitude and decreases the frequency 
of cardiac contractions and would therefore be of value in reducing blood loss 
during surgery [150]. It also inhibits the action of narcotics and hypnotics, and 
increases the analgesic effect of morphine [149], as well as the 
pharmacological effects of caffeine, carbazole, arecoline and nicotine [126]. 
 
3.8. Other alkaloids 
  
 Cherylline is a 4-arylisoquinoline derivative, a group with several 
potential medicinal properties [188], including a weak acetylcholinesterase 
inhibitory activity [118]. Mesembrenone, in turn, is mildly active against Molt 
4 lymphoid and non-tumoral fibroblastic LMTK cells [84], has a moderate 
hypotensive effect on arterial pressure and interacts slightly with DNA 
[99,140]. 
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